The oral protein and oral peptide market is expected to reach USD 1.4 billion in 2022 anticipated to grow at a CAGR of 20% during the forecast period 2022-2032

Since the introduction of the initial protein-based therapy, recombinant human insulin, in 1982, there has been a significant surge in research and development dedicated to such medicinal products. Initially administered subcutaneously, technological advancements in delivery formulations have catalyzed the ascent of orally administered therapeutic interventions. This transition has piqued the interest of stakeholders, leading to a focused effort on crafting proteins and peptides suitable for oral ingestion. Notably, within the last decade, three peptide-based therapies?Mycapssa? (2020), Trulance? (2017), and Linzess? (2012)?have secured FDA approval, making successful market entries across various global regions. The escalating popularity of this emerging therapeutic category has spurred the reformulation and advancement of oral protein and peptide-based treatments for numerous disease indications spanning metabolic, gastrointestinal, and autoimmune disorders.
The oral delivery of peptide pills presents distinct advantages, especially for pediatric and geriatric patients, owing to its non-invasive nature. Furthermore, its straightforwardness has demonstrated an ability to improve treatment adherence while reducing the likelihood of non-compliance. Protein and peptide-based therapeutics have profoundly influenced the pharmaceutical landscape due to their diverse applications and targeted therapeutic properties. Nonetheless, formulating these drugs for oral intake has encountered challenges, including low bioavailability and susceptibility to degradation within the gastrointestinal tract. To confront these obstacles, companies operating in the oral protein and peptide market have undertaken extensive research, focusing on innovating novel biological targets to fortify their research pipelines. This particular industry segment has garnered significant attention from private and public sector investors who have provided considerable financial support to drive these initiatives. Notably, major pharmaceutical companies have increasingly engaged in this sector, resulting in substantial partnership activities.
Given the ongoing research and development endeavors alongside the favorable reception of already commercialized drugs, the market for oral protein and peptide therapies is poised for substantial growth in the forecasted period.

Report Coverage
? Summary of key research insights on the current state and future evolution of the oral protein/peptide therapeutics market.
? Introduction comparing small molecules and large molecules (biologics), discusses proteins/peptides as therapeutic agents, explores drug delivery routes, and examines challenges and advantages of oral administration.
? Details over 125 programs for oral protein/peptide therapeutics, analyzing their phases, target areas, mechanisms, and developer information.
? A competitive analysis of therapy developers based on parameters like pipeline strength and development phase.
? A competitive analysis of therapy developers based on parameters like pipeline strength and development phase.
? An insight derived from the study, featuring schematic representations of the product pipeline and developer companies.
? Identification of key opinion leaders (KOLs) in the field, assessing their experience and contributions.
? Prime target indications for oral proteins/peptides, detailing disease epidemiology, diagnostic tests, treatment options, and likely side effects.
? Detailed profiles of marketed or late-stage oral protein/peptide drugs, including development history, mechanisms, clinical trials, and developer information.
? Technology platforms for oral protein/peptide development and the companies involved based on establishment year, size, and headquarters.
? Product competitiveness and supplier power of oral drug delivery technology platforms based on several parameters.
? Profiles of key technologies used in oral protein/peptide therapeutics, including mechanisms, pipeline molecules, advantages, and partnerships.
? Detailed investments received by companies in this field, analyzing funding instances based on parameters like amount invested, focus area, and geographical analysis.
? Detailed collaborations established since 2017, categorizing them by type, focus area, partner type, and regional distribution.
? An in-depth analysis of patents related to oral protein/peptides filed or granted since 2017, including geographical distribution, legal status, and leading players.
? Big pharma players engaged in oral protein/peptide therapeutics based on pipeline candidates, partnerships, and publications.
? A detailed market forecast analysis, projecting the growth of oral protein/peptide therapeutics till 2032 based on various segmentation parameters.

Key Market Companies
? Anthera Pharmaceuticals
? Carmot Therapeutics
? IGY Life Sciences and Technology
? Constant Therapeutics